2017-10-03 08:00:00
Draft Agenda (Subject to Change)
Day 1, Tuesday, October 3 |
|
| 8:30 a.m. – 9:00 a.m. | Welcome and Introduction Piotr Grodzinski, Ph.D. National Cancer Institute, National Institutes of Health Paula Jacobs, Ph.D. Doug Lowy, M.D. |
| Session I – Efficient Delivery across Stromal Barriers and through Tumor Microenvironment Moderator: Christina Liu, Ph.D., P.E. National Cancer Institute, National Institutes of Health |
|
| 9:00 a.m. – 9:30 a.m. | Disruption between Tumor Cells and the Bone Marrow Microenvironment as a Novel Strategy for Sensitization of Multiple Myeloma John F. DiPersio, M.D., Ph.D. Washington University in St. Louis |
| 9:30 a.m. – 9:50 a.m. | The Use of Nano-enabled stromal vascular Engineering and Immune Intervention for the treatment of Pancreatic Cancer Huan Meng, Ph.D. University of California at Los Angeles |
| 9:50 a.m. – 10:10 a.m. | Delivery across Dense Stromal Tissue for Imaging and Therapy Hui Mao, Ph.D. Emory University |
| 10:10 a.m. – 10:25 a.m. | Break (15 minutes) |
| 10:25 a.m. – 10:45 a.m. | Targeted Core Shell Nanogels for Effective Delivery to Triple Negative Breast Cancer Alexander Kabanov, Ph.D., D.Sc. University of North Carolina at Chapel Hill |
| 10:45 a.m. – 11:00 a.m. | Alliance 2016 Pilots: Spherical Nucleic Acids for Targeting the Glioma Microenvironment Alexander Stegh*, Ph.D., and Justin Lathia, MD Northwestern University and Cleveland Clinic |
| 11:00 a.m. – 11:15 a.m. | Alliance 2016 Pilots: Treatment of Glioblastoma Using Chain-like Nanoparticles Directed to PTPm Efstathios Karathanasis*, Ph.D. and Susann Brady-Kalnay, Ph.D. Case Western Reserve University |
| 11:15 a.m. – 12:00 p.m. | Session I – Panel Discussion Chair: John F. DiPersio, M.D., Ph.D. Washington University in St. Louis |
| 12:00 p.m. – 1:00 p.m. | Lunch |
| 1:00 p.m. – 2:30 p.m. | Cancer Nanotechnology Training Centers – Trainee Oral Presentations
Arvin Gouw, Ph.D., Stanford University CNTC Emily Evans, UT MD Anderson CNTC Kevin Metcalf, Ph.D., Northwestern University CNTC Joanna Wang, Ph.D., University of California at San Diego CNTC Myungjun Ko, Johns Hopkins University CNTC Emily B Harrison, PhD., University of North Carolina CNTC |
| Session II – Metastatic Cancer: Nanoscale Delivery and Detection Moderator: Christopher M Hartshorn, Ph.D. National Cancer Institute, National Institutes of Health |
|
| 2:30 p.m. – 2:50 p.m. | Combining nanotechnology and radiotherapy to improve cancer immunotherapy Andrew Wang, M.D. University of North Carolina |
| 2:50 p.m. – 3:10 p.m. | Small molecule drug delivery to brain tumors via ultrasmall silica nanoparticles Cameron Brennan, M.D. Memorial Sloan Kettering Cancer Center |
| 3:10 p.m. – 3:30 p.m. | Development of Nano-immunotherapy and subsequent Efficacy on Lung Metastases Wenbin Lin, Ph.D. University of Chicago |
| 3:30 p.m. – 4:15 p.m. | Session II – Panel Discussion Chair: Michelle Bradbury, M.D., Ph.D. Memorial Sloan Kettering Cancer Center |
| 4:15 p.m. – 6:00 p.m. | Poster Session |
| 5:00 p.m. – 6:15 p.m. | Coordination and Governance Committee Meeting (by invitation only) |
Day 2, Wednesday, October 4 |
|
| Session III – Emerging Strategies for Translation of Nanoscale Delivery Systems to Clinical Use Moderator: Piotr Grodzinski, Ph.D. National Cancer Institute, National Institutes of Health |
|
| 8:45 a.m. – 9:15 a.m. | SNAs for Immunotherapies David Giljohann, Ph.D. Exicure |
| 9:15 a.m. – 9:45 a.m. | Development and Testing of Diagnostic Platforms at T2 Biosystems Tom Lowery, Ph.D. Chief Scientific Officer, T2 Biosystems |
| 9:45 a.m. – 10:15 a.m. | Targeted Nanotherapies as well as Patient Stratification Techniques to Enhance their Efficacy Daryl Drummond, Ph.D. Head of Research, Merrimack Pharmaceuticals |
| 10:15 a.m. – 10:30 a.m. | Break (15 minutes) |
| 10:30 a.m. – 12:00 p.m. | Special Panel: Future Directions for Cancer Nanotechnology (led by Greg Lanza) |
| 12:00 p.m.- 1:00 p.m. | Lunch |
| Session IV – Recent IRCNs, CNTC and Pilots Moderator: Stephanie Morris, Ph.D. National Cancer Institute, National Institutes of Health |
|
| 1:00 p.m. – 1:20 p.m. | Mechanical Drugs: Harnessing Cancer Aggressiveness to Overcome Its Resistance Dmitri Lapotko, Ph.D. Masimo Corporation |
| 1:20 p.m. – 1:40 p.m. | Targeted therapeutics for ovarian cancer and its microenvironment – treatment and theoretical modeling Gabriel Lopez-Berestein, M.D. University of Texas, MD Anderson Cancer Center |
| 1:40 p.m. – 2:00 p.m. | Optimizing RNA Nanoparticle’s Size and Shape for Enhancing Cancer Targeting and Treatment Peixuan Guo, Ph.D. Ohio State University |
| 2:00 p.m. – 2:20 p.m. | Imaging of Nanotherapeutic Drug Action Miles Miller, Ph.D. Center for Systems Biology, Massachusetts General Hospital |
| 2:20 p.m. – 2:40 p.m. | UCSD Cancer Research in Nanotechnology – CNTC Andy Kummel, Ph.D. University of California at San Diego |
| 2:40 p.m. – 3:00 p.m. | Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology Nicole Steinmetz, Ph.D. Case Western Reserve University |
| 3:00 p.m. – 3:20 p.m. | Break (20 minutes) |
| 3:20 p.m. – 3:40 p.m. | Alliance 2016 Grand Challenges: Remodeling the Suppressive Tumor Microenvironment of Pancreatic Cancer to Facilitate Immunotherapy Limei Shen*, Ph.D., Leaf Huang, Ph.D. and Lily Yang, M.D., Ph.D. University of North Carolina at Chapel Hill and Emory University |
| 3:40 p.m. – 4:00 p.m. | Alliance 2016 Pilots: Novel Radiohalogenation Strategies for Enhancing Imaging and Targeted Radiotherapy Michael McDevitt, Ph.D., M.E. Memorial Sloan Kettering and Duke University Medical Center |
| 3:40 p.m. – 4:00 p.m. | Alliance 2016 Grand Challenges: Treatment of Glioblastoma by Targeting Neoplastic Pericytes Disrupts the Blood-Tumor Barrier to Enhance Delivery of Chain-Like Nanoparticles Efstathios Karathanasis, Ph.D., Jeremy Rich, M.D., Wei Wei, Ph.D., and David Nathanson*, Ph.D. Case Western Reserve University, University of California, San Diego, and UCLA |
| 4:00 p.m. – 4:20 p.m. | Alliance 2016 Grand Challenges: Treatment of Glioblastoma by Targeting Neoplastic Pericytes Disrupts the Blood-Tumor Barrier to Enhance Delivery of Chain-Like Nanoparticles Efstathios Karathanasis, Ph.D., Jeremy Rich, M.D., Wei Wei, Ph.D., and David Nathanson*, Ph.D. Case Western Reserve University, University of California, San Diego, and UCLA |
| 4:20 p.m. – 4:40 p.m. | Alliance 2016 Pilots: eNanoBook and Data Sharing Alexander Tropsha, Ph.D. University of North Carolina at Chapel Hill |
| 4:45 p.m. – 6:00 p.m. | Poster Session |
Day 3, Thursday, October 5 |
|
| Session V – Nanoenabled Diagnostics and High-throughput Screening: Monitoring Therapeutic Response Moderator: Christopher M Hartshorn, Ph.D. National Cancer Institute, National Institutes of Health |
|
| 8:45 a.m. – 9:30 a.m. | Session Keynote: Molecular Signatures of Circulating Tumor Cells Daniel Haber, M.D., Ph.D. Massachusetts General Hospital Cancer Center and Harvard Medical School |
| 9:30 a.m. – 9:45 a.m. | Student Poster Award Presentation |
| 9:45 a.m. – 10:05 a.m. | CTC Capture and Purification to Elucidate Precision Patient Response to Therapy Hsian-Rong Tseng*, Ph.D. / Edwin Posadas, M.D. University of California at Los Angeles / Cedars-Sinai Medical Center |
| 10:05 a.m. – 10:25 a.m. | Direct In Vivo Measurement of Therapeutic Response Jianghong Rao, Ph.D. Stanford University |
| 10:25 a.m. – 10:55 a.m. | Liquid Biopsy: Clinical Perspective of CTC and ctDNA Applications Julie Lang, M.D. University of Southern California, Norris Comprehensive Cancer Center |
| 10:55 a.m. – 11:15 a.m. | Break (20 minutes) |
| 11:15 a.m. – 11:35 a.m. | Tools for Monitoring and Defining Cancer Immunotherapies Jim Heath, Ph.D. California Institute of Technology |
| 11:35 a.m. – 11:55 a.m. | Multiscale Nanotechnologies for Comprehensive Assessment of Lung Cancer in Blood Shan X. Wang, Ph.D. Stanford University |
| 11:55 a.m. – 12:15 p.m. | Novel CTC Purification Modalities via Nanotechnology Sunitha Nagrath, Ph.D. University of Michigan |
| 12:15 p.m. – 1:00 p.m. | Session V – Panel Discussion Chair: Daniel Haber, M.D., Ph.D. Massachusetts General Hospital Cancer Center and Harvard Medical School |
| 1:00 p.m. – 1:15 p.m. | Summary and Closing Comments Piotr Grodzinski, Ph.D. National Cancer Institute, National Institutes of Health |
| 1:15 p.m. | Adjournment |
* Denotes speaker for presentation
Capital Consulting Corporation